Methods A cost-effectiveness analysis was carried out for photodynamic therapy (PDT) performed in early stage lung cancer cases, which by definition have no lymph node metastasis. The alternative treatment method was lobectomy, which conventionally would have been the first choice of treatment. Costs (C) and effectiveness (E) both of the PDT group and operation group were compared. Effectiveness was determined using quality adjusted life years saved (QALYs) which is the 5-year survival rate adjusted in terms of the quality of life of the patient, and the cost-effectiveness rate was obtained based on the costs of treatment methods during the patient's stay in the hospital. Health care costs, including drugs, were calculated according to the 1992 National Health Insurance list in yen. Costs which were non-reimbursable by the public insurance system, such as for special rooms and sun block cream, were also expressed in yen.
INTRODUCTION
Lung cancer remains the leading cause of cancer death in most Western countries. Despite thousands ofclinical trials, the introduction ofnew approaches to management, and improvements in supportive care, the outlook for most patients diagnosed with carcinoma of the lung remains poor. The rising demand for health care services coupled with static or decreasing resources with which to pay for them has resulted in increasing interest in the economic analysis of medical interventions [1] [2] [3] . In this situation, the merits of new cancer therapy are now compared not only in terms of effectiveness but also cost of treatment.
Photodynamic therapy (PDT), a relatively new modality used in the treatment of cancer, has gained considerable acceptance in the past decade [4, 5] . A wide variety of malignancies have been treated by this method and according to literature, over 3000 patients worldwide have been treated with PDT [6] . In Japan, PDT with photofrin and excimer dye laser obtained government approval in October 1995 and finally obtained national insurance reimbursement status in April 1996 [7] .
This article analyzes the cost-effectiveness in Japan of the new cancer treatment method, PDT, for early stage lung cancer.
MATERIALS AND METHODS

Estimate of Costs
The following basic assumptions were made:
(1) Disease: early stage lung cancer (TisNOM0) [8] . (2) (2) C2---cost of drug injection (Table II) The cost of drug injection consists of costs for the intravenous (i. (4) C4-cost of diagnostic imaging (Table IV) Fewer chest X-rays were required for the PDT group.
(5) C5 cost of treatment (Table V) Since the cost of bronchial toilet after PDT is included in C3, the cost of treatment for the PDT (Table VI) The cost ofoperation includes lobectomy, use ofone automatic suture device, anesthesia, antibiotics, and local hemostatic agents, etc. Concerning the anesthesia, it was assumed that closed circulatory systemic anesthesia is performed for 5 h, in addition to epidural anesthesia, monitoring of subcutaneous arterial oxygen saturation and neural block.
It was decided to estimate the running cost of the excimer dye laser and the technical charge. Assuming that one excimer dye laser costs 40,000,000 and is used for 6 years, the annual depreciation is 6,670,000. The running cost for year can be obtained by adding the maintenance fee (routine checkup fee, part exchange fee, janitorial fee, etc.) of 2,500,000, laser dye of 300,000, and laser gas of 200,000 to the above 6,670,000. Assuming that 50 patients will undergo this procedure per year, the running cost for one patient is obtained by dividing the running cost for one year by 50 plus 40,000 for the light transmission fiber and 1000 for electricity (234,400). Adding these up, the total cost of the procedure is assumed to be 500,000. In addition, since PDT only requires local anesthesia for bronchofiberscopy, which is already included in the examination category cost, the cost of local anesthesia is not included in this section. (Table VII) The cost of diagnosis for both operated and PDT groups includes 1950 for initial examination and 5000 for management of the records of malignant tumor treatment.
Concerning the costs related to hospital stay, it was assumed that patients receive regular food, use a regular bed and pajamas and receive high quality RESULTS Table VIII shows the total cost for the operated group and the PDT group from C1 to C8. The total cost of the operated group was 1,793,832 and that for the PDT group was 1,017,104.
In this analysis the end point of the treatment is set as 5-year survival and the cost-effectiveness is estimated on a monthly basis. This study used QALY units were used to indicate effectiveness in this study.
Using the costs and effectiveness discussed above, the rates ofcost-effectiveness ofthe two groups were compared. The cost-effectiveness rate of the operated group, that is the average cost of treatment per postoperative living month, was 37,537, while that of the entire PDT group was 30,003. This indicates that the cost-effectiveness rate for the operated group is apparently 1.3 times lower than that of the PDT group. The monthly cost-effectiveness rate for the PDT group of lesions smaller than 2 cm was 25,533. Therefore the cost in the operated group is 1.5 times higher. [12, 13] . Since then, 370 cases, including 240 lung cancer patients (283 lesions), were treated with PDT in our institution. There were several cases of 5-year survival, including the first such case in the world treated by PDT alone [14] .
DISCUSSION
PDT has no serious side effects apart from sensitivity to sunlight. It was also apparent that it not only reduces the psychological and physical burden on patients but also is a therapy with high economical cost-effectiveness in the Japanese medical environment. In addition, PDT has the advan- Average lengths of survival were adjusted using the rate ofdecrease in %VC as an index of quality of life, and this was used to indicate true effectiveness, expressed in terms of QALYs. This is in principle similar to Karnofsky's performance status, in which method QOL is indicated by the patient's ability to perform various activities [15] . In these analyses the number of data is often limited and analysis is restricted to some extent. Analysis of a long-term model could be possible if data on multiple cancer, rate of recurrence, rate of survival, etc. were available.
Even in Japan, where its people have lived under the protection and security of its health plan, the country's health budget is now in jeopardy. For instance, in the treatment for cancer, there was a great tendency to turn to surgery alone. However, the current way of treatment emphasizes the patient's needs and QOL greatly while maintaining cost-effectiveness. As a result ofthis "new" tendency, the number of minor invasive treatment cases, such as PDT, bave been increasing. With the development of second generation photosensitizers, which produce no skin photosensitivity, patients treated with PDT may now possibly be admitted for a shortened term; thereby contributing to the cost effectiveness of Japan's health budget.
